Immune deficiencies due to defects in cytokine signaling

Current Allergy and Asthma Reports

Volumn 3, Issue 5, 2003, Pages 396-401

  Kelly, John ^a   Leonard, Warren J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ANTIINFECTIVE AGENT; CD45 ANTIGEN; CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; IMMUNOGLOBULIN; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 21; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 9 RECEPTOR; JANUS KINASE; LYMPHOCYTE ANTIGEN RECEPTOR; ONCOPROTEIN; PROTEIN KINASE ZAP 70; PROTEIN P55; RAG1 PROTEIN; RAG2 PROTEIN; RECEPTOR SUBTYPE; STAT PROTEIN;

ANTIMICROBIAL THERAPY; B LYMPHOCYTE; CELL FUNCTION; CELL MATURATION; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; DISEASE SEVERITY; GENE TARGETING; GENETIC ANALYSIS; GENETIC DISORDER; HUMAN; IMMUNE DEFICIENCY; INFECTION SENSITIVITY; LEUKEMIA; LYMPHOCYTE COUNT; LYMPHOID CELL; MYCOBACTERIOSIS; NATURAL KILLER CELL; NONHUMAN; PROTEIN DEFICIENCY; REVIEW; SIGNAL TRANSDUCTION; STEM CELL GENE THERAPY; T LYMPHOCYTE; TREATMENT PLANNING; TUBERCULOSIS; X CHROMOSOME LINKED DISORDER; CHILD; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY;

CHILD; CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; SEVERE COMBINED IMMUNODEFICIENCY; SIGNAL TRANSDUCTION;

EID: 0142026058     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-003-0073-y     Document Type: Review

References (57)

1. Leonard WJ: Type 1 cytokines and interferons and their receptors. In Fundamental Immunology, edn 4. Edited by Paul WE. Philadelphia: Lippincott Raven; 1999:771-774.
2. Leonard WJ, O'Shea JJ: JAKS and STATS: biological implications. Annu Rev Immunol 1998, 16:293-322.
3. Darnell JE Jr: STATs and gene regulation. Science 1997, 277:1630-1635.
4. Buckley RH, Schiff RI, Schiff SE, et al.: Human severe combined immunodeficiency: genetic, phenotypic, and functional deversity in one hundred eight infants. J Pediatr 1997, 130:378-387.
5. Leonard WJ: Cytokines and immunodeficiency diseases. Nat Rev Immunol 2001, 1:200-208.
6. Noguchi M, Yi H, Rosenblatt HM, et al.: Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993, 73:147-157.
7. Frucht DM, Gadina M, Jagadeesh GJ, et al.: Unexpected and variable phenotypes in a family with JAK3 deficiency. Genes Immunol 2001, 2:422-432.
8. c with JAK1 and JAK3: implications for XSCID and XCID. Science 1994, 266:1042-1045.
9. c and Jak3 double-deficient mice. Int Immunol 2000, 12:123-132.
10. Puel A, Ziegler SF, Buckley RH, Leonard WJ: Defective IL7R expression in T-B+NK+ severe combined immunodeficiency. Nat Genet 1998, 20:394-397.
11. Kennedy MK, Glaccum M, Brown SN, et al.: Reversible defects in natural killer and memory CD8T cell lineages in interleukin 15-deficient mice. J Exp Med 2000, 191:771-780.
12. Lodolce JP, Boone DL, Chai S, et al.: IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998, 9:669-676.
13. Suzuki H, Kundig TM, Furlonger C, et al.: Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 1995, 268:1472-1476.
14. Gilmour KC, Fujii H, Cranston T, et al.: Defective expression of the interleukin-2/interleukin-15 receptor beta subunit leads to a natural killer cell-deficient form of severe combined immunodeficiency. Blood 2001, 98:877-879.
15. Peschon JJ, Morrissey PJ, Grabstein KH, et al.: Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 1994, 180:1955-1960.
16. Ozaki K, Spolski R, Feng CG, et al.: A critical role for IL-21 in regulating immunoglobulin production. Science 2002, 298:1630-1634.
17. Kasaian MT, Whitters MJ, Carter LL, et al.: IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 2002, 16:559-569.
18. Takeda K, Noguchi K, Shi W, et al.: Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 1997, 94:3801-3804.
19. Nakajima H, Liu XW, Wynshaw-Boris A, et al.: An indirect effect of Stat5a in IL-2-induced proliferation: a critical role for Stat5a in IL-2-mediated IL-2 receptor alpha chain induction. Immunity 1997, 7:691-701.
20. Imada K, Bloom ET, Nakajima H, et al.: Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med 1998, 188:2067-2074.
21. Moriggl R, Topham DJ, Teglund S, et al.: Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 1999, 10:249-259.
22. Kelly J, Spolski R, Imada K, et al.: A role for Stat5 in CD8+ T cell homeostasis. J Immunol 2003, 170:210-217.
23. Buckley RH, Schiff SE, Schiff RI, et al.: Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999, 340:508516.
24. Haddau E, Landais P, Friedrich W, et al.: Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood 1999, 91:3646-3653.
25. Ting SS, Tangye SG, Wood J, et al.: Reduced memory B-cell populations in boys with B-cell dysfunction after bone marrow transplantation for X-linked severe combined immunodeficiency. Br J Haematol 2001, 112:1004-1011.
26. Fischer A, Hacein-Bey S, Cavazzana-Calvo M: Gene therapy of severe combined immunodeficiencies. Nat Rev Immunol 2002, 2:615-621.
27. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al.: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288:669-672.
28. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al.: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002, 346:1185-1193.
29. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al.: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003, 348:255-256.
30. Marshall E: Gene therapy: second child in French trial is found to have leukemia. Science 2003, 299:320.
31. Mosmann TR, Cherwinski H, Bond MW, et al.: Two types of murine helper T cell clone: definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136:2348-2357.
32. Hsieh C-S, Macatonia SE, Tripp CS, et al.: Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993, 260:547-549.
33. Seder RA, Gazzinelli R, Sher A, Paul WE: Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon α production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA 1993, 90:10188-10192.
34. Remus N, Reichenbach J, Picard C, et al.: Impaired interferon g-mediated immunity and susceptibility to mycobacterial infection in childhood. Pediatr Res 2001, 50:8-13.
35. Casanova J-L, Abel L: Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 2002, 20:581-620.
36. Newport MJ, Huxley CM, Huston S, et al.: A mutation in the interferon-g-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996, 35:1941-1949.
37. Jouanguy E, Altare F, Lamhamed S, et al.: Interferon-g-receptor deficiency in an infant with bacille Calmette-Guérin infection. N Engl J Med 1996, 335:1956-1961.
38. Dorman SE, Holland SM: Mutation in the signal-transducing chain of the interferon-g receptor and susceptibility to mycobacterial infection. J Clin Invest 1998, 101:2364-2369.
39. Jouanguy E, Lamhamedi-Cherradi S, Altare F, et al.: Partial interferon-g-receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guérin infection and a sibling with clinical tuberculosis. J Clin Invest 1997, 101:2658-2664.
40. Döffinger R, Jouanguy E, Dupuis S, et al.: Partial interferon-g-receptor signaling deficiency in a patient with bacillus Calmette-Guérin and mycobacterium abscessus infection. J Infect Dis 2000, 181:379-384.
41. Altare F, Durandy A, Lammas D, et al.: Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998, 280:1432-1435.
42. De Long R, Altare F, Haagen I-A, et al.: Severe mycobacterial and salmonella infections in interleukin-12 receptor-deficient patients. Science 1998, 280:1435-1438.
43. Altare F, Lammas D, Revy P, et al.: Inherited interleukin-12 deficiency in a child with bacillus Calmette-Guérin and Salmonella enteritidis disseminated infection. J Clin Invest 1998, 102:2035-2040.
44. Okamura H, Tsutsi H, Komatsu T, et al.: Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995, 379:88-91.
45. Pflanz S, Timans JC, Cheung J, et al.: IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induced proliferation of naive CD4+ T cells. Immunity 2002, 16:779-790.
46. Meraz MA, White JM, Sheehan KC, et al.: Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996, 84:431-442.
47. Durbin JE, Hackenmiller R, Simon MC, Levy DE: Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996, 84:443-450.
48. Gil MP, Bohn E, O'Guin, et al.: Biologic consequences of Stat1-independent IFN signaling. Proc Natl Acad Sci USA 2001, 98:6680-6685.
49. Dupuis S, Dargemont C, Fieschi C, et al.: Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 2001, 293:300-303.
50. Dupuis S, Jouanguy E, Al-Hajjar S, et al.: Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiency. Nat Genet 2003, 33:388-391.
51. Holland SM, Eisenstein EM, Kahuns DB, et al.: Treatment of refractory nontuberculous mycobacterial infection with interferon gamma: a preliminary report. N Engl J Med 1994, 330:1348-1355.
52. Condos R, Rom WN, Schluger NW: Treatment of multidrug-resistant pulmonary tuberculosis with interferon-g via aerosol. Lancet 1997, 349:1513-1515.
53. Doherty TM, Sher A: IL-12 promotes drug-induced clearance of mycobacterium avium infection in mice. J Immunol 1998, 160:5428-5435.
54. Deng JC, Tateda K, Zeng X, Standiford TJ: Transient transgenic expression of gamma interferon promotes Legionella pneumophilia clearance in immunocompetent hosts. Infect Immun 2001, 69:6382-6390.
55. Wasserman D, Ioannovich JD, Hinzmann RD, et al.: Interferon-gamma in the prevention of severe burn-related infection. Crit Care Med 1998, 26:434-439.
56. Rigato O, Salamao R: Impaired production of interferon-g and tumor necrosis factor-a but not interleukin 10 in whole blood of patients with sepsis. Shock 2003, 19:113-116.
57. Nakos G, Malamou-Mitsi VD, Lachana A, et al.: Immuno-paralysis in patients with severe trauma and the effect of inhaled interferon-g. Crit Care Med 1998, 30:1488-1494.